Advertisement
J. Lipid Res.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1194/jlr.R800089-JLR200 on December 12, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
R800089-JLR200v1
50/Supplement/S412    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Erickson, S. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Erickson, S. K.
Related Collections
Right arrow Related Webpages
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Journal of Lipid Research, Vol. 50, S412-S416, April 2009
Copyright © 2009 by American Society for Biochemistry and Molecular Biology

Lipids in Health and Disease

Nonalcoholic fatty liver disease

Sandra K. Erickson1

Department of Medicine, University of California, San Francisco, CA 94121; and Veterans Affairs Medical Center, San Francisco, CA 94121

The author's work is supported by a Merit Award from the Department of Veterans Affairs and by DK-072187 from the National Institutes of Health.

Published, JLR Papers in Press, December 12, 2008.

1 To whom correspondence should be addressed. e-mail: sandra.kerickson{at}ucsf.edu


ABSTRACT

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the United States and, indeed, worldwide. It has become a global public health issue. In the United States, the prevalence in the general population is estimated at ~20%, while that in the morbidly obese population at ~75-92% and in the pediatric population at ~13–14%. The progressive form of NAFLD, nonalcoholic steatohepatitis, is estimated at ~3–5%, with ~3–5% of these having progressed to cirrhosis. Thus, the numbers of individuals at risk for end-stage liver disease and development of primary liver cancer is large. NAFLD is an independent risk factor for cardiovascular disease, leads to increased all-cause mortality, and to increased liver-related mortality. This review focuses on recent advances in our understanding of the NAFLD disease spectrum, including etiology, diagnosis, treatment, and genetic and environmental risk factors and suggests future directions for research in this important area.

Supplementary key words steatohepatitis • fibrosis • cirrhosis • liver tumors • cardiovascular disease • obesity • diabetes


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


Related Webpages:

JLR 50th Anniversary Collections
Anniversary Collection:: Lipids in Health and Disease



HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2009 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement